Trial Profile
Phase I Study of Ruxolitinib With Radiation and Temozolomide in Patients With Newly Diagnosed Grade III Gliomas and Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions
- 11 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2024.
- 16 Aug 2023 Planned End Date changed from 1 Jun 2023 to 31 Dec 2024.
- 16 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 31 Dec 2023.